Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
OBIO vs CVM: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CVM Captures Overall Composite Edge (43.5 HOLD vs 42.9 HOLD), While OBIO Leads 3–2 on Growth & Valuation Pillars
CVM Overall Winner
6-Pillar Tally: OBIO 3 – 2 CVM (1 Tie)
Matrix Metrics: OBIO 4 – 6 CVM
As of Nov 17, 2026, Cel-Sci Corporation (CVM) captures the overall head-to-head institutional edge over Orchestra BioMed Holdings, Inc. (OBIO) on higher Unified Composite conviction (43.5/100 HOLD vs. 42.9/100 HOLD) after splitting the core matrix 6–4 (led by Valuation Multiples, Profitability & Quality), while OBIO wins 3–2 across the 6-pillar growth and valuation breakdown. OBIO trades at $6.97 (N/M Forward P/E, -195.4% operating margin) versus CVM at $1.85 (23.0x Forward P/E, 0.0% operating margin).
- Growth vs. Quality Trade-Off: CVM earns the overall head-to-head edge with a stronger Unified Composite Score (43.5/100 HOLD vs. OBIO 42.9/100 HOLD) and 0.42β · 140% Vol risk profile, whereas OBIO leads top-line expansion (-89.4% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: OBIO trades in a Markup technical trend (BREAKOUT options phase, RSI 68.1); meanwhile CVM is in a Breakdown options structure phase (RSI 61.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About OBIO vs CVM
OBIO
Orchestra BioMed Holdings, Inc. Ordinary Shares
$6.97
-2.11% 1D
Market Cap
$570.6M
TTM Revenue
$31M
Forward P/E
N/M
Beta / 30D Vol
1.16β · 80% Vol
Unified Composite Score
42.9
HOLD
Tech 15.0
Fund 40.0
Flow 62.0
Mom 44.0
Weinstein Technical Phase
Markup · Hold / add on dips
CVM
Head-to-Head Winner
Cel-Sci Corporation
$1.85
+11.45% 1D
Market Cap
$22.5M
TTM Revenue
$28,558
Forward P/E
23.0x
Beta / 30D Vol
0.42β · 140% Vol
Unified Composite Score
43.5
HOLD
Tech 23.0
Fund 47.0
Flow 50.0
Mom 54.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (OBIO 3 – 2 CVM)
1. Valuation Multiples
CVM
Forward P/E
N/M
23.0x
Trailing P/E
N/M
23.0x
PEG Ratio
N/M
1.12x
EV / Revenue
18.6x
N/M
2. Growth & Scale
OBIO
Revenue Growth (YoY)
-89.4%
-62.7%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$31M
$28,558
Market Cap
$570.6M
$22.5M
3. Profitability & Quality
CVM
Gross Margin
99.6%
N/A
Operating Margin
-195.4%
0.0%
Net Profit Margin
-182.5%
0.0%
Return on Equity (ROE)
-182.3%
-252.5%
4. Balance Sheet & Cash Flow
OBIO
Cash Generation (TTM)
-$64M
-$17M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$9.0M Net Debt (4.72x D/E)
$6.6M Net Debt (1.24x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
OBIO
Options Structure Phase
BREAKOUT
BREAKDOWN
Current IV / %ile
70.8% (<1st %ile)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
ACCUMULATION · Markup
ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: OBIO (4) vs CVM (6)| Institutional Metric | OBIO | CVM | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $570.6M | $22.5M | OBIO | |
| Trailing P/E Ratio | N/M | 23.0x | CVM | |
| Forward P/E Ratio | N/M | 23.0x | CVM | |
| Revenue Growth (YoY) | -89.4% | -62.7% | CVM | |
| Operating Margin (TTM) | -195.4% | 0.0% | CVM | |
| Net Profit Margin | -182.5% | 0.0% | CVM | |
| Return on Equity (ROE) | -182.3% | -252.5% | OBIO | |
| 52-Week Range Position | 88% ($3–$7) | 14% ($1–$8) | OBIO | |
| Beta / 30D Volatility | 1.16β · 80% Vol | 0.42β · 140% Vol | OBIO | |
| Unified Institutional Score | 42.9 / 100 (HOLD) | 43.5 / 100 (HOLD) | CVM | |
| Trailing 12M Revenue (USD) | $31M | $28,558 | Scale | |
| Gross Profit Margin (TTM) | 99.6% | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 18.6x EV/Rev | 1.12x PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$64M ($9.0M Net Debt (4.72x D/E)) | -$17M ($6.6M Net Debt (1.24x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
OBIO +11.24 pp
3M Horizon
OBIO +12.79 pp
6M Horizon
OBIO +57.9 pp
1Y Horizon
OBIO +148.95 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | OBIO Revenue | CVM Revenue | OBIO Op. Margin | CVM Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2011 | N/A | $0M | N/A | -1881.0% | CVM |
| FY2012 | N/A | $0M | N/A | -6772.3% | CVM |
| FY2013 | N/A | $0M | N/A | -12450.1% | CVM |
| FY2014 | N/A | $0M | N/A | -9721.4% | CVM |
| FY2022 | $0M | N/A | -924.3% | N/A | OBIO |
| FY2023 | $0M | N/A | -1866.2% | N/A | OBIO |
| FY2024 | $0M | N/A | -2437.5% | N/A | OBIO |
| FY2025 | $30M | N/A | -154.7% | N/A | OBIO |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
OBIO
BREAKOUT
Current IV
70.8%
IV Percentile
<1st %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact OBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
CVM
BREAKDOWN
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
ACCUMULATION
Exact CVM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
OBIO Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
CVM Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ OBIO vs CVM Key Questions & Quantitative Answers
As of Nov 17, 2026, Cel-Sci Corporation (CVM) captures the overall head-to-head institutional edge over Orchestra BioMed Holdings, Inc. (OBIO) on higher Unified Composite conviction (43.5/100 HOLD vs. 42.9/100 HOLD) after splitting the core matrix 6–4 (led by Valuation Multiples, Profitability & Quality), while OBIO wins 3–2 across the 6-pillar growth and valuation breakdown. OBIO trades at $6.97 (N/M Forward P/E, -195.4% operating margin) versus CVM at $1.85 (23.0x Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: CVM earns the overall head-to-head edge with a stronger Unified Composite Score (43.5/100 HOLD vs. OBIO 42.9/100 HOLD) and 0.42β · 140% Vol risk profile, whereas OBIO leads top-line expansion (-89.4% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: OBIO trades in a Markup technical trend (BREAKOUT options phase, RSI 68.1); meanwhile CVM is in a Breakdown options structure phase (RSI 61.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
OBIO leads the Growth & Scale pillar: OBIO posts -89.4% YoY revenue growth and +0.0% YoY earnings growth on $31M TTM revenue (99.6% gross margin, -195.4% operating margin), compared with CVM at -62.7% YoY revenue growth and +0.0% YoY earnings growth on $28,558 TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2011 to FY2025), OBIO cumulative revenue shifted N/A while CVM shifted N/A. In operating R&D and SG&A reinvestment, OBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CVM.
CVM screens cheaper on headline valuation multiples. OBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 18.6x EV/Revenue (unreported FCF margin), whereas CVM trades at 23.0x Forward P/E, 23.0x Trailing P/E, 1.12x PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OBIO (-182.3% ROE) versus CVM (-252.5% ROE) capital efficiency.
In options market volatility and institutional positioning, OBIO carries 70.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.16β · 80% Vol realized risk). By comparison, CVM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.42β · 140% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
CVM vs OBIO · Reverse Pair
OBIO vs OABI
· Sector Peer
CVM vs AGEN
· Sector Peer
CVM vs BCRX
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking